AI in Drug Development — The Evidence Problem, Not the Data Problem
CONCEPTHealthcare and pharmaceutical industry experts increasingly argue that AI's bottleneck in drug development is not data scarcity but rather insufficient clinical evidence demonstrating that AI-discovered or AI-optimized compounds actually outperform traditional drug discovery methods in human trials. While AI excels at pattern recognition and molecular optimization in silico, the field lacks robust prospective studies comparing AI-driven drug candidates to conventionally discovered compounds in terms of efficacy, safety, and clinical outcomes. Wolters Kluwer and other industry voices note that AI vendors often emphasize computational efficiency and time-to-candidate rather than clinical superiority. Addressing the evidence gap requires large-scale, long-term clinical trials comparing AI-discovered drugs head-to-head with conventional pipelines—a costly and time-intensive undertaking. Until this evidence accumulates, pharmaceutical companies remain cautious about AI integration despite significant R&D investments. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.